HBMN:SWX
HBM Healthcare Investments AG
233,50 CHF
arrow_upward
+0,65%(+1,50) 1 d
30 apr., 13:15:18 GMT+2 · CHF
search
Alla symboler
1 d
5 d
1 m
6 m
Hittills i år
1 år
5 år
MAX
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för HBMN …
Öppen
231,50 CHF
Högt
233,50 CHF
Lågt
228,00 CHF
Börsvärde
1,57 md
Genomsn. vol.
6,47 tn
Volym
730,00
Utdelning
3,21 %
Kvartalsvis utdelning
1,88 CHF
Ex-utdelningsdatum
2 juli 2025
P/E-tal
6,50
52v högst
245,50 CHF
52v lägst
157,40 CHF
EPS
35,93 CHF
Utestående aktier
6,74 mn
Nyheter och artiklar
Från källor på webben
Simply Wall Street
·
för 14 minuter sedan
GE HealthCare Technologies Q1 Margins Hold At 10.1% Net Level Testing Bullish Narratives
Stock Titan
·
för 32 minuter sedan
Novocure (NASDAQ: NVCR) grows Q1 revenue and raises 2026 outlook
Yahoo Finance
·
för 47 minuter sedan
Strategic Education's (NASDAQ:STRA) Strong Earnings Are Of Good Quality
Seeking Alpha
·
för 1 timme sedan
AM Markets Need to Know: Social security funds, Strait of Hormuz coalition, and more (SP500:)
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Om HBM Healthcare Investments AG
AI-innehåll kan innehålla fel. Läs mer